Spero Therapeutics, Inc. Restructuring Charges
Spero Therapeutics, Inc. (SPRO) reported Restructuring Charges of $0 for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2026-08-12
- Spero Therapeutics, Inc. restructuring charges for the quarter ending 2026-06-30 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. restructuring charges for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. restructuring charges for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Spero Therapeutics, Inc. restructuring charges for the quarter ending 2025-09-30 was $0.00.
- Spero Therapeutics, Inc. restructuring charges for fiscal 2025 was $258.00K, a 70.58% decline from fiscal 2024.
- Spero Therapeutics, Inc. restructuring charges for fiscal 2024 was $877.00K.
- Spero Therapeutics, Inc. restructuring charges for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Spero Therapeutics, Inc. restructuring charges for fiscal 2022 was $11.63M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $0.00 derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 derived: sum of 3 quarters · filed 2026-05-13 | $83.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $83.00K derived: sum of 3 quarters · filed 2026-08-12 | $258.00K 10-K · filed 2026-03-26 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $83.00K derived: sum of 2 quarters · filed 2026-08-12 | $258.00K 10-Q · filed 2025-11-13 | $1.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $83.00K 10-Q · filed 2026-08-12 | $258.00K 10-Q · filed 2026-08-12 | $1.14M derived: sum of 3 quarters · filed 2026-08-12 | $1.14M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $175.00K 10-Q · filed 2026-05-13 | $1.05M derived: sum of 2 quarters · filed 2026-05-13 | $1.05M derived: sum of 3 quarters · filed 2026-05-13 | $1.05M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $877.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $877.00K derived: sum of 2 quarters · filed 2026-03-26 | $877.00K derived: sum of 3 quarters · filed 2026-03-26 | $877.00K 10-K · filed 2026-03-26 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-12 | $0.00 10-Q · filed 2025-08-12 | $0.00 derived: sum of 3 quarters · filed 2025-08-12 | $0.00 derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $0.00 derived: sum of 3 quarters · filed 2025-05-13 | $0.00 derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $0.00 derived: sum of 2 quarters · filed 2025-03-27 | $0.00 derived: sum of 3 quarters · filed 2025-03-27 | $0.00 10-K · filed 2025-03-27 |
| 2023-09-30 | $0.00 10-Q · filed 2023-11-13 | $0.00 derived: sum of 2 quarters · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | -$67.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | -$67.00K derived: sum of 3 quarters · filed 2024-03-13 | -$219.00K derived: sum of 4 quarters · filed 2024-03-13 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | -$67.00K derived: sum of 2 quarters · filed 2024-03-13 | -$219.00K derived: sum of 3 quarters · filed 2024-03-13 | $11.63M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-12-31 | -$67.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$219.00K derived: sum of 2 quarters · filed 2024-03-13 | $11.63M derived: sum of 3 quarters · filed 2024-03-13 | $11.63M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$152.00K 10-Q · filed 2023-11-13 | $11.70M derived: sum of 2 quarters · filed 2023-11-13 | $11.70M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $11.85M 10-Q · filed 2023-08-10 | $11.85M 10-Q · filed 2023-08-10 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $0.00 derived: sum of 2 quarters · filed 2023-03-30 | $0.00 derived: sum of 3 quarters · filed 2023-03-30 | $0.00 10-K · filed 2023-03-30 |
| 2021-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2022-11-14 | $0.00 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $0.00 10-Q · filed 2022-08-10 | $0.00 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 |